PRESS RELEASE published on 05/21/2026 at 22:00, 1 month 2 days ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Inventiva to present at 2026 Jefferies Global Healthcare Conference in New York City. CEO Andrew Obenshain to speak on June 3, 2026, about MASH therapies Clinical-Stage Biopharmaceutical Inventiva Lanifibranor 2026 Jefferies Conference MASH Therapies
PRESS RELEASE published on 05/21/2026 at 22:00, 1 month 2 days ago Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference à New York City son traitement oral pour la stéatohépatite. Détails de la présentation le 3 juin 2026 Inventiva Lanifibranor Stéatohépatite 2026 Jefferies Global Healthcare Conference Traitement Oral
BRIEF published on 05/13/2026 at 08:35, 1 month 11 days ago Inventiva présentera des résumés au congrès EASL 2026 Recherche Biopharmaceutique Inventive Lanifibranor Traitement MASH Congrès EASL 2026
BRIEF published on 05/13/2026 at 08:35, 1 month 11 days ago Inventiva presents its research on lanifibranor at the EASL Congress 2026 Biopharmaceutical Inventiva MASH Lanifibranor EASL Congress 2026
BRIEF published on 05/13/2026 at 08:35, 1 month 11 days ago Inventiva to Present Abstracts at EASL Congress 2026 Biopharmaceutical Research Inventiva Lanifibranor MASH Treatment EASL Congress 2026
BRIEF published on 05/13/2026 at 08:35, 1 month 11 days ago Inventiva présente ses recherches sur le lanifibranor au EASL Congress 2026 Biopharmaceutique Inventiva MASH Lanifibranor EASL Congress 2026
PRESS RELEASE published on 05/13/2026 at 08:30, 1 month 11 days ago Inventiva to Present Abstracts at the EASL Congress 2026 Inventiva to present two abstracts at EASL Congress 2026 highlighting Lanifibranor's impact on MASH treatment. Lanifibranor, a pan-PPAR agonist, shows promising results in clinical trials Clinical Trials Inventiva Lanifibranor MASH Treatment EASL Congress 2026
PRESS RELEASE published on 05/13/2026 at 08:30, 1 month 11 days ago Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026 Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026. Découvrez les détails des présentations et la présence de la société au congrès Biopharmaceutique Inventiva MASH Lanifibranor EASL Congress 2026
BRIEF published on 04/22/2026 at 22:05, 2 months 1 day ago Inventiva renforce son équipe de direction à l'approche d'une étape clé de la phase 3. Essai De Phase 3 Lanifibranor Développement Du Leadership Traitement MASH Inventiva Biopharmaceutique
BRIEF published on 04/22/2026 at 22:05, 2 months 1 day ago Inventiva Bolsters Executive Team as It Nears Key Phase 3 Data Milestone Phase 3 Trial Lanifibranor Leadership Expansion MASH Treatment Inventiva Biopharmaceutical
Published on 06/24/2026 at 03:15, 6 hours 27 minutes ago Noram Lithium Adopts Semi-Annual Financial Reporting
Published on 06/24/2026 at 00:00, 9 hours 42 minutes ago Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Published on 06/23/2026 at 23:45, 9 hours 57 minutes ago Prospect Ridge Aligns with the Market Mindset for Exclusive Live Investor Interview Discussing Game-changing 2026 Drill Programs
Published on 06/23/2026 at 23:20, 10 hours 22 minutes ago BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/23/2026 at 23:15, 10 hours 27 minutes ago EV Nickel Signs LOI Forming High-Grade Nickel Joint Venture for Shaw Dome Projects
Published on 06/24/2026 at 09:37, 5 minutes ago KNDS ANNOUNCES INTENTION TO PROCEED WITH AN IPO TO SUPPORT ITS LONG-TERM GROWTH STRATEGY
Published on 06/24/2026 at 09:34, 7 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 06/24/2026 at 09:00, 42 minutes ago Yellow Card Can Now Offer Regulated Virtual Asset and Related Services from Switzerland
Published on 06/24/2026 at 09:30, 12 minutes ago CP HOPENING - Le 1er Baromètre “Libéralités - Grande Transmission”
Published on 06/23/2026 at 19:47, 13 hours 54 minutes ago GROUPE SFPI: reorganisation de la Direction Générale
Published on 06/23/2026 at 19:47, 13 hours 54 minutes ago GROUPE SFPI: General management reorganisation
Published on 06/23/2026 at 19:10, 14 hours 31 minutes ago GUILLEMOT CORPORATION > EVOLUTION DE LA GOUVERNANCE A COMPTER DU 23 JUIN 2026
Published on 06/23/2026 at 19:10, 14 hours 31 minutes ago GUILLEMOT CORPORATION: Changes to Corporate Governance Effective June 23, 2026
